Evidence map›Paper›PMID 25668009›Full record

ArticleBritish journal of cancer2015

MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.

R F H Walter, F D Mairinger, S Ting, C Vollbrecht, T Mairinger, D Theegarten, D C Christoph, K W Schmid, J Wohlschlaeger

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 26 citations in OpenAlex.

  1. Role of the MDM2/p53 axis in regulating cisplatin response in tumor cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Malignant pleural mesothelioma: an update.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2021
    Review
  7. Double Empirical Bayes Testing.International statistical review = Revue internationale de statistique · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. An evaluationOncotarget · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. The Roles of MDM2 and MDMX in Cancer.Annual review of pathology · 2016
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

R F H Walter1] Ruhrlandklinik, West German Lung Center, University Hospital Essen, University of Duisburg-Essen, Tüschener Weg 40, Essen D-45239, Germany [2] Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
F D MairingerInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
S TingInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
C VollbrechtInstitute of Pathology, University Hospital Cologne, Cologne, Germany.
T MairingerDepartment of Pathology, Helios Klinikum Emil von Behring, Berlin, Germany.
D TheegartenInstitute of Pathology, University Hospital Cologne, Cologne, Germany.
D C Christoph1] Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany [2] Department of Medicine, Division of Medical Oncology, University of Colorado Denver, Aurora, CO, USA.
K W SchmidInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
J WohlschlaegerInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
University of Duisburg-Essen · DEUniversity Hospital Cologne · DEHelios Klinikum Emil von Behring · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant pleural mesothelioma (MPM) is a highly aggressive tumour that is first-line treated with a combination of cisplatin and pemetrexed. Until now, predictive and prognostic biomarkers are lacking, making it a non-tailored therapy regimen with unknown outcome. P53 is frequently inactivated in MPM, but mutations are extremely rare. MDM2 and P14/ARF are upstream regulators of P53 that may contribute to P53 inactivation.

methodsA total of 72 MPM patients were investigated. MDM2 immunoexpression was assessed in 65 patients. MDM2 and P14/ARF mRNA expression was analysed in 48 patients of the overall collective. The expression results were correlated to overall survival (OS) and progression-free survival (PFS).

resultsOS and PFS correlated highly significantly with MDM2 mRNA and protein expression, showing a dismal prognosis for patients with elevated MDM2 expression (for OS: Score (logrank) test: P⩽0.002, and for PFS: Score (logrank) test; P<0.007). MDM2 was identified as robust prognostic and predictive biomarker for MPM on the mRNA and protein level. P14/ARF mRNA expression reached no statistical significance, but Kaplan-Meier curves distinguished patients with low P14/ARF expression and hence shorter survival from patients with higher expression and prolonged survival.

conclusionsMDM2 is a prognostic and predictive marker for a platin-pemetrexed therapy of patients with MPMs. Downregulation of P14/ARF expression seems to contribute to MDM2-overexpression-mediated P53 inactivation in MPM patients.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsCyclin-Dependent Kinase Inhibitor p16FemaleGene Expression Regulation, NeoplasticGlutamatesGuanineHumansMaleMesotheliomaMiddle AgedOrganoplatinum CompoundsPemetrexedPleural NeoplasmsProto-Oncogene Proteins c-mdm2Antineoplastic AgentsCyclin-Dependent Kinase Inhibitor p16GlutamatesGuanineMDM2 protein, humanOrganoplatinum CompoundsPemetrexedProto-Oncogene Proteins c-mdm2TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID25668009
PMCPMC4453955
OpenAlexW2057110758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.